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BACKGROUND: Although the routine use of treatment plans and summaries (TPSs) has been recommended to improve the quality of
cancer care, limited data exist about their impact on quality, including patient satisfaction and coordination of care. METHODS:
Patients received TPSs as part of the American Society of Clinical Oncology Breast Cancer Registry (BCR) pilot program of 20 com-
munity oncology practices. Participants were surveyed 2 to 4 weeks after receiving a TPS to evaluate their perceptions of the docu-
ment. Patients who were receiving chemotherapy received the TPS as separate plan and summary documents (at the start and the
end of treatment) and could complete 2 surveys. Others received a single integrated TPS. Eligible survey participants had stage 0
through III breast cancer and were enrolled in the BCR. RESULTS: Of 292 consented patients, 174 (60%) completed at least 1 survey.
Of 157 patients who recalled receiving a TPS, 148 (94%) believed that the documents improved patient-physician communication, and
128 (82%) believed that they improved communication between physicians; 113 (72%) said the documents increased their peace of
mind, whereas 2 (1%) had less peace of mind. Of 152 patients (97%) who still had their documents, 147 (97%) said they were useful,
and 94 (62%) had given or planned to give the documents to another physician. All 63 patients who were surveyed after receiving a
summary recommended that practices continue to provide TPSs to patients. CONCLUSIONS: Participants in this study expressed
high satisfaction with TPSs. Additional research is needed to study the broad-scale implementation of the BCR and to evaluate the
impact of routine use of TPSs on the quality of care delivered. Cancer 2013;119:164-72.VC 2012 American Cancer Society.
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INTRODUCTION
The oncology workforce is shrinking relative to the increasing number of cancer survivors, and a possible solution is to
transition survivors to the care of primary care physicians (PCPs) after an adequate period of surveillance by the oncology
practitioner.1,2 Because breast cancer survivors represent nearly 25% of all cancer survivors in the United States, much
attention has been focused on this group.3 Research has demonstrated that almost half of PCPs feel unprepared to care for
cancer survivors, and most believe they receive insufficient information about their patients’ cancer diagnoses and treat-
ments.3-5 Patients also report that a major limitation in survivorship care is inadequate communication between oncolo-
gists and PCPs, and breast cancer survivors have reported feelings of anxiety and abandonment after completing their
treatment.6-9 Only 41% of breast cancer patients believe that their PCPs know how to treat symptoms related to cancer or
associated therapies.10 Communication problems also exist between patients and physicians during the treatment period,
when survivors report confusion about the chemotherapy schedule and expected side effects.8,11 Integrating survivorship
care plans into the practice of oncology has emerged as a possible solution to these problems and has been recommended
as an important step in improving the quality of cancer care by several recent reports and organizations, including the
American Society of Clinical Oncology (ASCO) and the Institute of Medicine.12-16
DOI: 10.1002/cncr.27856, Received: January 3, 2012; Revised: May 4, 2012; Accepted: May 17, 2012, Published online November 29, 2012 in Wiley Online
Library (wileyonlinelibrary.com)
Corresponding author: Victoria S. Blinder, MD, MSc, Department of Epidemiology and Biostatistics, Center for Health Policy and Outcomes, Memorial
Sloan-Kettering Cancer Center, 300 East 66th Street, 14th Floor, New York, NY, 10065; Fax: (646) 227-7102; blinderv@mskcc.org
1Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York; 2American Society of Clinical Oncology, Alexandria,
Virginia; 3Tennessee Oncology, PLLC, Nashville, Tennessee; 4Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan Medical
School, Ann Arbor, Michigan; 5Department of Biostatistics, Dana-Farber Cancer Institute, Boston, Massachusetts; 6Department of Medicine, Weill Cornell Medical
College, New York, New York; 7Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; 8Department of
Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, Massachusetts.
See editorial on pages 4-6 and related article on pages 158-63, this issue.
We gratefully acknowledge all of the patients and practices who participated in the pilot as well as the Outcome Sciences and American Society of Clinical On-
cology staff for their support of this study.
164 Cancer January 1, 2013
Original Article
In previous research, survivors who had finished
treatment reacted favorably to the idea of both treatment
and survivorship care plan documents and said that they
would have liked to have received such documents as part
of their care.6,8,9,11,17 In a small, qualitative study, breast
cancer survivors reacted favorably to personalized survi-
vorship care plans administered 2 weeks after treatment
completion.7 In contrast, a recent randomized controlled
trial of survivorship care plans administered to Canadian
breast cancer survivors who were at least 3 months post-
treatment did not demonstrate an associated benefit in
terms of quality of life or patient satisfaction.18 However,
none of the results published to date include patients’ per-
ceptions of plans that were incorporated into their care at
the time of treatment initiation, when they may be most
important in facilitating communication with the treating
clinician.
ASCO developed online templates as tools oncolo-
gists can use to improve physician-patient and physician-
physician communication.19 These 2-page templates are
different from many other survivorship care plans,
because they exist with 2 distinct parts—a treatment plan
and a treatment summary. The Breast Cancer Adjuvant
Treatment Plan Template, which is used when the patient
starts the adjuvant regimen, includes information about
the agents prescribed, anticipated treatment schedule, and
possible side effects. It also includes clinical data about the
patient, such as date and type of breast surgery, tumor
stage and characteristics, and family history. The Treat-
ment Summary Template is used when the patient com-
pletes the regimen and includes information from the
treatment plan as well as the dates when treatments were
completed, cumulative doses of relevant drugs (eg, anthra-
cyclines), toxicities experienced by the patient, and survi-
vorship care recommendations. These templates may be
completed, printed, incorporated into the medical record,
and shared with the patient and other providers.
Although several treatment plan and summary
(TPS) templates have been developed, we know little
about patients’ reactions to receiving such documents. To
address this gap in the literature, we evaluated patient per-
spectives regarding the integration of TPSs based on the
ASCO templates into their clinical care. This study was
part of a larger program, the ASCO Breast Cancer Regis-
try (BCR) Pilot Program, which entailed the creation of a
registry of patients enrolled through 20 US community
oncology practices. Registry data were used to create cus-
tomized TPSs to be shared with patients. In this report,
we describe the perspectives of patients who participated
in a research survey as part of the BCR Pilot Program. A
separate report documents implementation of the registry
and the perspectives of participating oncology practices
regarding the BCR.20
MATERIALS AND METHODS
Setting
Twenty diverse oncology practices from the ASCO mem-
bership were selected to participate in the BCR. The
recruitment of oncology practices to our study and their
training in the use of the registry are described in an
accompanying article.20 Briefly, practices were selected to
optimize diversity in practice size, type of practice
(academic vs community), geographic location, patient
population (including languages spoken and insurance
type), and participation in the ASCO Quality Oncology
Practice Initiative.
Each practice appointed a site principal investigator
who was responsible for overseeing the patient informed-
consent process at that site. The New England Institu-
tional Review Board approved the study on behalf of
ASCO and 13 of the participating practices. Seven prac-
tices obtained approval from their own institutional
review boards.
Study Participants
Practice staff entered treatment plan and summary data
into the BCR for all newly diagnosed patients with stage 0
through III breast cancer who received treatment from a
participating oncologist during the pilot. Practices were
instructed to offer all patients TPSs and to discuss the
documents with patients (Fig. 1). Practice staff deter-
mined the structure of these discussions. Patients who
were receiving chemotherapy received the TPS as separate
plan and summary documents (at the beginning and end
of treatment, respectively). Others received a single inte-
grated TPS. After at least 4 months of registry participa-
tion by a practice, the practice staff began to consent and
enroll participants in the patient survey study. Patients
who accepted the TPSs were eligible to participate in the
survey study if they read and spoke English and were aged
18 years. Each practice was instructed to recruit consec-
utive patients to the survey study until 10 patients from
that practice had completed a survey or the survey period
concluded. Patients were surveyed between March 2010
and November 2010.
Data collection
The survey study started only after practices had
become familiar with using the registry and sharing the
TPS documents with patients. Participants who received
chemotherapy had the opportunity to complete a
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Figure 1. This is a blank American Society of Clinical Oncology breast cancer treatment planning form. ICD-9-CM indicates Inter-
national Classification of Diseases, Ninth Revision, Clinical Modification; AJCC, American Joint Committee on Cancer; Her2Neu,
human epidermal growth factor receptor; ER, estrogen receptor; PR, progesterone receptor; ECOG, Eastern Cooperative Oncol-
ogy Group; BSA, body surface area.
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telephone survey twice, 2 to 4 weeks after receiving a treat-
ment plan and 2 to 4 weeks after receiving a summary.
Although the intent was to obtain 2 surveys from each
patient who received chemotherapy, because of time and
funding constraints of this pilot study, we allowed patients
who were not surveyed after they received a treatment
plan to complete a survey after they finished treatment
and received a summary. However, all patients who
received chemotherapy received both a treatment plan
and a treatment summary document, regardless of the
number of surveys they completed. Those who did not
receive chemotherapy were offered a single survey 2 to 4
weeks after receiving an integrated TPS. The surveys
occurred 2 to 4 weeks after the receipt of a document so
that participants would have time to process and share the
document if they wished to do so. An independent survey
vendor, Alan Newman Research (available at: http://
www.anr.com/home.html [Accessed October 12, 2012]),
administered the telephone surveys and made up to 10
attempts to contact each consented patient.
Study instruments
A study steering committee comprised of ASCO
volunteers, staff, and expert consultants developed the
surveys to assess patient perceptions of the coordination
of their care and the quality of communication with their
oncologists. The three 15-minute to 20-minute surveys
(post-treatment plan, post-treatment summary, and post-
integrated TPS) were similar in questions and scope,
although some questions differed in the tense used and
the name of the document discussed. Participants used a
4-point scale to rate their understanding of the TPS and
their treatment, the impact of the TPS on communication
with and between clinicians, the usefulness of the TPS
and likelihood that they would refer back to it, the
amount of information received, and the amount of sup-
port provided by the medical oncologist and other health
professionals overall during treatment. Participants also
indicated whether the TPS gave them greater or less peace
of mind or whether it had no impact. In the postsummary
survey, participants indicated whether they recommended
that their physicians continue providing TPS documents
to their patients (yes, no, not sure). Participants could sug-
gest improvements to the TPSs in response to 3 open-
ended questions asking: 1) what, if anything they liked
about the documents; 2) what, if anything, they disliked
about the documents; and 3) whether they had any sug-
gestions or comments for improving the information in
the documents.
Analysis
Given the similarities between the treatment plan, sum-
mary, and integrated plan/summary documents, and in
light of similarities between the corresponding surveys, we
conducted a single analysis of the data from all of the sur-
veys. The data set included the responses to 1 survey from
each participant regardless of whether the responses were
obtained after a treatment plan, summary, or combined
document was given to the participant. Only 8 partici-
pants completed 2 surveys, and we included only the
responses from the second survey.
Because this was a pilot study, most planned analyses
were exploratory and descriptive. We analyzed patient sat-
isfaction by asking whether or not participants recom-
mended that practices continue to provide the documents
to their patients. Additional related outcomes that were
assessed in all surveys included participant perceptions of
the documents’ impact on their peace of mind, prepara-
tion for treatment, communication with physicians, com-
munication between physicians, and clinician support.
Verbatim transcripts of answers to the 3 open-ended ques-
tions were analyzed by a single investigator (V.S.B.)
according to the themes that emerged. Formal qualitative
methodology and qualitative research software were not
deemed necessary for this straightforward analysis, and
they were not used. The themes were summarized, and
salient quotations representing each are presented.
RESULTS
Of 292 eligible, consented participants, 174 (60%) from
18 different practices completed a survey (Fig. 2). Clinical
and demographic characteristics of both the study and
Figure 2. This chart illustrates recruitment flow.
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registry samples are summarized in Table 1. Survey partic-
ipants were more likely to be white (17% of registry par-
ticipants did not have race/ethnicity recorded) and to have
received chemotherapy than the registry sample as a
whole, but the cancer stage distribution of the 2 groups
was similar. Within the survey sample, 66% did not have
a 4-year college degree, whereas 42% had an annual
household income <$60,000. Of 174 participants sur-
veyed, 157 (90%) said they remembered receiving a TPS,
and 152 of those participants (97%) said they still had the
document.
Almost 75% of participants who remembered
receiving a TPS reported that the document gave them
greater peace of mind, 24% said it made no difference,
and 1% said the document gave them less peace of mind
(Table 2). Ninety-seven percent of participants who still
had their TPS said the document was ‘‘useful.’’ Ninety
percent of participants said they were likely to refer back
TABLE 1. Participant Characteristics
No. of Participants (%)
Characteristic
Patient Survey
Participants, n ¼ 174
Registry Participants,
n ¼ 2014
Age: Median [range] 58 [27-87] 59 [21-95]
Sex
Women 171 (98) 2004 (99)
Men 3 (2) 10 (1)
Race/ethnicitya
White, non-Latino 146 (84) 1169 (58)
African-American 16 (9) 205 (10)
Latino 3 (2) 78 (4)
Asian 2 (1) 108 (5)
American Indian or Alaska Native 2 (1) 6 (<1)
Other 4 (2) 18 (1)
Don’t knowb 1 (1) 89 (4)
Not reported 345 (17)
Disease stage
0: DCIS 13 (7) 270 (13)
I 68 (39) 773 (38)
II 51 (29) 535 (26)
III 20 (11) 192 (9)
IVb 0 (0) 10 (<1)
Not sure 19 (11) 234 (12)
Refused to respondb 3 (2)
Treatment received or planned at time of surveyc
Chemotherapy alone 86 (49) 329 (16)
Endocrine therapy alone 40 (23) 893 (44)
Chemotherapy and endocrine therapy 10 (6) 565 (28)
No chemotherapy or endocrine therapy 29 (17) 227 (11)
Not sureb 5 (3)
Refused to respondb 4 (2)
Educationd
Did not finish high school 7 (4)
High school diploma or GED 35 (20)
Some college or 2-y degree 72 (41)
Four-y college degree 23 (13)
Graduate studies or degree 35 (20)
Refused to respond 2 (1)
Annual household incomed
<$20,000 18 (10)
$20,000-$40,000 27 (16)
$40,000-$60,000 28 (16)
$60,000 76 (43)
Don’t know/refused to respond 25 (14)
Abbreviations: DCIS, ductal carcinoma in situ; GED, General Educational Development.
aOne or more race could be selected in the registry (sum of categories, >2014).
b This information was not an available response in the registry.
c Practices reported difficulty consenting patients who did not receive chemotherapy because of practice flow.
d This information was not collected by the registry.
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to the document as they received treatment or in the
future. All 63 participants who answered a postsummary
survey recommended that their practice continue to pro-
vide TPSs to patients (this question was only asked in the
postsummary survey).
Ninety-four percent of all participants who remem-
bered receiving a TPS reported that the document had
improved or would improve communication between
themselves and their physicians (Table 2). Eighty-two per-
cent said they thought the document had improved or
would improve communication between their different
health care providers. Sixty-two percent said they had
given or would give their TPS to another physician, such
as their PCP (data not shown), and 97% of those partici-
pants thought it would be useful to the physician. Only
3% said they thought the document would be not at all
useful.
Ninety-eight percent of participants said they
understood their TPS (Table 2). Of 136 participants who
received or planned to receive systemic therapy (chemo-
therapy, endocrine therapy, or both), 96% said they were
prepared for what to expect from their treatment (Table
3). Overall, 69% of all participants said they had received
about the right amount of information regarding their
cancer and its treatment, whereas 16% said they received
more information than was needed, and 13% said they
received less than was needed (Table 3).
Seventy-one percent of participants reported that
their oncologists discussed the TPS with them. Only 20%
said they discussed it with someone else in the practice,
such as a nurse, and 8% reported that nobody in the prac-
tice discussed the document with them. Eighty-five per-
cent thought the individual who discussed the summary
with them did so ‘‘very well’’ (13% said ‘‘moderately
well’’). Greater than 66% of participants believed they
received about the right amount of support from their
medical oncologist and other health professionals,
whereas 19% said they received more support than was
needed (Table 3). Only 9% received less support than was
needed. Greater than 75% of participants indicated that
their medical oncologist listened to them ‘‘very much,’’
and 18% said their oncologist listened to them ‘‘moder-
ately.’’ Similar proportions said their oncologist answered
their questions (87% said ‘‘very much,’’ and 10% said
‘‘moderately’’).
Participants’ Comments in Response to
Open-Ended Questions
Participants were asked to comment on what, if anything,
they liked and disliked about the TPSs. They also were
TABLE 2. Patient Satisfaction and Communication With Physicians
Patient Perceptions: No. of Participants (%), n ¼ 157a
Perceptions About Communication Very Much Moderately A Little Not At All
Not
Sure/Refused
The patient understood the document 115 (73.2) 36 (22.9) 3 (1.9) 1 (0.6) 1 (0.6)/1 (0.6)
The document improved communication with physician 90 (57.3) 51 (32.5) 7 (4.4) 2 (1.3) 5 (3.2)/2 (1.3)
The document improved communication between physicians 83 (52.9) 40 (25.5) 5 (3.2) 7 (4.4) 20 (12.7)/2 (1.3)
The document is or will be useful, n ¼ 152b 104 (68.4) 35 (23) 8 (5.3) 3 (2) 1 (1.3)/0 (0)
Patient Perceptions: No. of Participants (%), n ¼ 157a
Perceptions About Peace of Mind Greater
No
Difference Less Not Sure Refused
Impact of the document on peace of mind 113 (72) 38 (24.2) 2 (1.3) 4 (2.5) 0 (0)
Patient Perceptions: No. of Participants (%), n ¼ 157a
Perceptions About Future Use of Document Very Likely
Somewhat
Likely
Not At
All Likely Not Sure Refused
The patient is likely to refer back to the document 88 (56) 54 (34.4) 13 (8.3) 1 (0.6) 1 (0.6)
Abbreviations: TPS, treatment plans and summaries.
a In total, 157 patients remembered receiving a TPS document.
b In total, 152 patients still had a TPS document.
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asked for suggestions on how to improve the documents.
Eighty-six percent of participants gave comments about
what they liked, including the clarity of the documents,
their use in communication with family and clinicians,
and an increased sense of empowerment. Participant com-
ments are summarized below, and salient participant quo-
tations are provided after each category.
The document was clear and concise: ‘‘It (the docu-
ment) just condenses everything. When you first hear even the
word ‘‘cancer,’’ it kind of jumbles everything in your mind. It
just condenses everything for me so that it is just easier for me
to know what to do. . .’’
Participants used the document to facilitate discus-
sions with family members: ‘‘My whole family knows how
long it’s going to go. It (the document) reduces their anxiety.
They know it’s going to be long and occur in 4 stages, and
they have met the people in each stage. We don’t have to pass
a lot of information to each other—just support. So they are
not asking questions about what is going to happen now, just
how we are going to handle it.’’
The document served as a tool to communicate with
the oncologist: ‘‘It’s a means for me to talk to my oncologist
about what they are fixing to do with me. Otherwise,
I wouldn’t even know what to say.’’
Participants liked being able to share the document
with other physicians to coordinate their care: ‘‘It kind of
lays it all out there. It gives all the other criteria for all the
other doctors. We are all on the same page.’’
The document brought some participants a sense of
empowerment and/or peace of mind: ‘‘I can check to see
the medication and the side effects, so I have the information
in my hand at all times. It is very useful when I’m informed
in detail. I feel like I’m in control instead of the victim.’’
Another participant said: ‘‘I like how it explains every-
thing. It is just peaceful. I can read it and understand every-
thing better.’’
Only 13% of participants mentioned something
they disliked, and 17% had a suggestion for improve-
ment. These comments described inaccuracies in individ-
ual documents, use of technical language, and need for
additional information about genetic testing, nutrition,
and treatment side effects.
DISCUSSION
Improved coordination of care has been proposed as an
important quality measure in cancer care in terms of both
clinical documentation of information needed by PCPs as
well as enhanced patient-provider communica-
tion.2,12,13,21 The use of TPS documents has been sug-
gested as an important step in achieving this goal, but the
impact of such documents remains unknown with respect
to coordination of care and patient perceptions and satis-
faction. In this pilot study, we observed that patients who
participated in the BCR survey pilot expressed high levels
of satisfaction with TPSs. Every participant who was
asked recommended that practices continue to supply
these documents. Almost 75% said the documents gave
them greater peace of mind. Most who recalled receiving a
TPS said they were likely to refer to it in the future and
that it was useful and improved patient-physician com-
munication. Participants also had favorable impressions
of the documents’ impact on coordination of care; greater
than 75% thought they improved communication
between physicians.
Our results indicate that the integration of TPS
documents into clinical care is feasible and desirable from
TABLE 3. Amount of Information and Support: Feeling Prepared for Treatment
Patient Perceptions: No. of Participants (%), n ¼ 174
Perceptions About Support More Than
Needed
About
Right
A Little Less
Than Needed
A Lot Less
Than Needed
Not Sure Refused
Support from medical oncologist and other health professionals 33 (19) 121 (69.5) 13 (7.5) 2 (1.1) 4 (2.3) 1 (0.6)
Information about cancer and treatment 28 (16.1) 120 (69) 21 (12.1) 1 (0.6) 4 (2.3) 0 (0)
Patient Perceptions: No. of Participants (%), n ¼ 174
Perceptions About Preparedness for Treatment Very Mucha Moderately A Little Not At All Not Sure Refused
Oncologist listened to patient 137 (78.7) 32 (18.4) 3 (1.7) 0 (0) 2 (1.1) 0 (0)
Oncologist answered patient’s questions 152 (87.4) 18 (10.3) 2 (1.1) 0 (0) 1 (0.6) 1 (0.6)
Patient felt prepared for what to expect from treatment, n ¼ 136b 77 (56.6) 48 (35.3) 6 (4.4) 3 (2.2) 1 (0.7) 1 (0.7)
Patient understood treatment received or planned, n ¼ 136b 89 (65.4) 41 (30.1) 3 (2.2) 0 (0) 1 (0.7) 2 (2.2)
a This response was ‘‘very well’’ for the last 2 questions in the table.
b In total, 136 patients received systemic therapy.
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the patient’s perspective. Nearly all participants under-
stood their TPS and thought the medical staff did a good
job discussing the document. In response to open-ended
questions about the documents, most gave positive feed-
back compared with relatively few who had any negative
comments.
To our knowledge, this is the first study to system-
atically examine patient perspectives on the integration of
TPS documents into clinical care at treatment initiation.
In prior research, survivors reacted favorably to blank
treatment plan templates, saying they wished they had
received a written plan at the start of treatment.10,11 Our
findings indicate that patients with breast cancer react
favorably when treatment plans are personalized and
implemented as part of their oncologic care. All of the par-
ticipants in our study received TPS documents at treat-
ment initiation, and almost all said they felt prepared for
what to expect from treatment and understood their
treatment.
Prior researchers have identified survivor preferences
with respect to the content and format of survivorship
care plans (similar to our treatment summaries) and have
demonstrated that survivors who did not receive these
documents supported their incorporation into survivor-
ship care.6,8,9,11,17 However, to date, there has been lim-
ited research describing survivors’ perceptions of the
inclusion of these documents in their clinical care. Our
findings are in contrast to those of Grunfeld et al, who
recently reported that breast cancer survivorship care plans
administered in randomized fashion at least 3 months
after treatment completion had no significant impact on
measures of cancer-related distress, continuity of care,
quality of life, or patient satisfaction in a Canadian sam-
ple.18 More than half of their study participants were
diagnosed at least 2 years before, and only 40% received
chemotherapy. The study design also differed from ours,
because all participants transferred care to a PCP after
completing a discharge visit with the oncologist, who also
sent a discharge letter to the PCP. Moreover, patient satis-
faction with clinical care was measured using the compre-
hensive Medical Outcomes Study-Patient Satisfaction
Questionnaire rather than a focused assessment of satisfac-
tion with and impressions of the document.22 The find-
ings from the study by Grunfeld et al are important,
because they challenge the tenet invoked by researchers,
professional organizations, and patient advocacy groups,
including ASCO and the Institute of Medicine, that survi-
vorship care plans will improve the quality of care and
that resources should be allocated to their implementa-
tion.12,13,15 However, in contrast to our study, the Grun-
feld et al study did not directly address the period of active
treatment or the early phase of transition from active can-
cer-directed therapy to primary care, and the results are of
limited generalizability to the United States, where the
lack of a national health insurance system may lead to fre-
quent changes in health providers and impaired continu-
ity of care, and where the transition back to primary care
does not consistently include an oncology discharge visit
and a discharge letter to the PCP.23
It is clear that patients are concerned about the lack
of coordination between primary oncologic care and fol-
low-up care, and they feel ill-equipped to navigate the
transition between these 2 health care settings.6,10,13,24
Less than 33% of patients think their PCPs and their
oncologists communicate well, and greater than 50% of
PCPs say the process of transfer of care to them from the
oncologist is fair/poor.5,10 TPS documents are a possible
solution to these problems, and our study indicates that
their use would be well received by patients.
Our study has several limitations, the majority of
which are because of the pilot nature of the research.
Although a much larger sample of practices is needed to
more accurately reflect the existing diversity in practice
type, the participating practices were selected as a repre-
sentative sample of community practices across the
United States. However, the participants in the patient
survey pilot are a subset of those in the registry, and it is
possible that there is systematic bias in the sample sur-
veyed. We do not have information about patients who
declined to participate. Those who participated in the sur-
vey were diverse in educational background and income,
but they were more likely to be white and to have received
chemotherapy than the registry sample as a whole, and
patients who receive complex treatment regimens may be
more likely to benefit from and demonstrate greater
appreciation for TPSs. It is also possible that our relatively
high survey refusal rate (46%) reflects the acceptability of
the TPS documents and that the documents were more
likely to be viewed as helpful and valuable by patients who
agreed to answer survey questions about them. However,
the existing literature, which suggests that most patients
approve of the concept of providing a TPS document,
supports our findings. Moreover, the practices in our
study reported that almost no patients declined to receive
a copy of their document(s), and most clinicians surveyed
(see the accompanying article by Partridge et al20) thought
that the majority of their patients found the documents
useful, which is also consistent with the findings presented
here. Another limitation is that, because of the small scale
and duration of this pilot study, we were unable to analyze
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patients’ reactions to the treatment plan and to the treat-
ment summary separately or to determine the characteris-
tics of those patients who were most likely to benefit from
the inclusion of these documents into their clinical care.
Additional research is needed to evaluate the impact
of the routine use of TPS documents on the quality of
cancer care delivered. Our findings contribute to the
groundwork for studies that examine the impact of these
documents on clinical and patient-reported outcomes in a
deterministic manner. In particular, the integration of the
treatment plan document into clinical care, a novel feature
of our study, merits additional research to determine the
impact of the document on patient satisfaction and
knowledge as well as treatment adherence and clinical out-
comes, all of which should be weighed against the associ-
ated costs.
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